CEO Kevin Sharer

Biotech drugmaker Amgen Inc. introduced new CEO Bob Bradway to shareholders Wednesday at the company's annual meeting, with retiring CEO Kevin Sharer stepping down after a decade running the world's largest biotech company. At the meeting, Amgen ...  

In 2011, Amgen's compensation programs were modified to reflect the core concerns of our stockholders and to better align executive pay with Amgen's performance. Today, Say-on-Pay received approximately 87 percent of the votes cast "For" the proposal.  

AMGEN, INC. : Amgen Sells $3 Billion In US Bond Market4-tradersBy Patrick McGee Of Amgen Inc. (AMGN) sold a $3 billion bond deal Thursday at some of the lowest yields ever for the company, thanks to ultralow Treasury rates coupled with strong demand. The Thousand Oaks, Calif.-based biopharmaceutical company sold ...and more »  

AMGEN, INC. : Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars4-tradersTHOUSAND OAKS, Calif., May 11, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Joseph P. Miletich, MD, Ph.D., senior vice president of Research and Development at Amgen will testify at the United States (US) Food and Drug Administration ...and more »  

ONTARIO - Officials estimate between 7,000 and 10,000 spectators, including Barry Bonds, came here on Saturday to watch Stage 7 of the Amgen Tour of California begin. Related story: Gesink takes overall lead with stage win Video: Amgen Tour 2012 Special Section: Amgen  

Equity Research on Spectrum Pharmaceuticals Inc. and Amgen Inc ...MarketWatch (press release)Today they are providing members comprehensive research on the Biotechnology industry and are offering free analytical research on Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) and Amgen Inc. (NASDAQ:AMGN) . Register with us today at ...and more »  

Amgen (AMGN) Q1 2012 Earnings Call April 24, 2012 5:00 pm ET Executives Arvind Sood - Vice President of Investor Relations Kevin W. Sharer - Chairman, Chief Executive Officer, Chairman of Executive Committee and Member of Equity Award Committee Robert A. Bradway - President, Chief Operating Officer and Director Jonathan M. Peacock - Chief Financial Officer and Executive Vice President Anthony C. Hooper - Executive Vice President of Global...  

Arvind Sood, vice president of Investor Relations at Amgen ... Follow us on www.twitter.com/amgen. 05/01 DJ Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales 05/01 DJ Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales 05/01 DJ Pfizer Profit ...  

Irish TimesAmgen Inc. (AMGN) Set A New High Following AcquisitionRTT News(RTTNews) - Amgen Inc. (AMGN: News ) announced Wednesday that it agreed to buy 95.6 percent of shares in Turkey's Mustafa Nevzat Pharmaceuticals in an all cash transaction, valuing the company at $700 million. Amgen gapped open higher Wednesday and ...Amgen Nears Deal to Acquire Turkish CompanyWall Street JournalAmgen to pay about $700 million for Turkish drug makerLos...  

Amgen Says BiTE Antibody Blinatumomab Achieved High Rate Of Complete ResponseRTT News(RTTNews) - Amgen Inc. (AMGN: News ) announced updated results from a Phase 2 study that showed treatment with blinatumomab or AMG 103 helped achieve a high-rate of complete response or CR in 72 percent of adult patients with relapsed or refractory ...and more »  

Amgen Revives Defunct Drug as Old Therapies Seek New CureBusinessWeekBy Ryan Flinn on May 17, 2012 Amgen Inc. (AMGN) (AMGN)'s experimental drug rilotumumab, set aside by the company after it disappointed in a study, has been revived after a fresh look at data in gastric cancer found it helped a group of patients.and more »  

New York, May 14th (TradersHuddle.com) - Amgen Inc. (NASDAQ:AMGN) closed the trading day at $70.78, near its 50 day moving average that is set at $68.28. Amgen's price action is just above this important support level, providing a trading opportunity.  

BloombergAmgen 1Q profit up 5 pct, beats Wall Street viewsSeattle Post IntelligencerFILE - In this April 21, 2010 file photo, the exterior view of Amgen Inc. offices is shown in Fremont, Calif. Amgen Inc. says first-quarter profit rose 5 percent on higher sales of its top two drugs and two new ones, and it easily beat Wall Street ...Amgen Profit Tops Analysts' Estimate on Rising Drug SalesBusinessWeekAnalysis: New Amgen CEO must win investors...  

Final Glance: Biotechnology companiesCBS NewsNEW YORK — Shares of some top biotechnology companies were down at the close of trading: Amgen Inc. fell $1.39 or 2.0 percent, to $69.15. Biogen Idec fell $1.30 or 1.0 percent, to $131.58. Celgene Corp. fell $.97 or 1.4 percent, to $68.10.and more »  

Notable ETF Inflow Detected - TQQQ, ALXN, ALTR, AMGNForbes(NASD: ALTR) is up about 0.1%, and Amgen Inc (NASD: AMGN) is lower by about 1.7%. For a complete list of holdings, visit the TQQQ Holdings page » Looking at the chart above, TQQQ's low point in its 52 week range is $25.63 per share, with $62.49 as the ...and more »